EIC Pathfinder Challenge: Cardiogenomics

Announcement "open"
I'm interested
European Commission
Internal deadline:
Official deadline:

EIC Pathfinder Challenges are designed to build on new, cutting-edge directions in science and technology to disrupt a field and a market or create new opportunities by realising innovative technological solutions grounded in high-risk/high-gain research and development. The EIC is seeking new technological solutions at early stage of development that are new and disrupt standard practice.

Cardiogenomics holds the potential to address existing gaps in the diagnosis and treatment of cardiovascular diseases (CVD), which would enable better outcome for the patient. Advanced genetic testing taking into account complex inheritance, or combining genetic testing, transcriptomics, proteomics and metabolomics analysis with clinical phenotype can improve clinical management of the CVD and identify more accurately, who is likely to be at risk for major cardiovascular events such as heart failure or sudden death.

The overall aim of this Challenge is to pave the way for novel therapies for major CVD conditions including haemorrhagic and ischemic stroke, aneurysm, cardiomyopathy and certain types of arrhythmias and other conditions, for which no effective treatments are currently available.

The following specific objectives have been identified:

  • To identify single or multiple gene variants of high biological significance or other key molecules associated with the CVDs that would allow for accurate stratification of patients and guide the physician in their clinical management and monitoring of these CVDs.
  • To identify novel targets based on these variants for specific CVD indication(s) that would allow for the development of first in class therapies for the same indication.
  • To seek for novel technological solutions that could contribute to the development and acceleration of first in class therapies for major CVD conditions for which no effective treatments are currently available.

Applicants must convincingly demonstrate that they have access to a large cohort of genomic and/or transcriptomics and/or proteomics and/or metabolomics database from CVD patients.

Grants of up to EUR 4 million (challenge driven) (or more if properly justified) to achieve the proof of principle and validate the scientific basis of breakthrough technology (TRL 1-4)


Proposals for this Challenge can be submitted by single applicants or by consortia, as dictated by the activities to be performed.


In case of interest please click on "m'interessa"  and we will contact you.